PMID- 25806261
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150325
LR  - 20200930
IS  - 2218-6751 (Print)
IS  - 2226-4477 (Electronic)
IS  - 2218-6751 (Linking)
VI  - 2
IP  - 5
DP  - 2013 Oct
TI  - Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): 
      implications for adjuvant therapy.
PG  - 415-22
LID - 10.3978/j.issn.2218-6751.2013.10.09 [doi]
AB  - The demonstration that systemic chemotherapy improves survival in patients who 
      have had resection of early stage non-small cell lung cancer (NSCLC) represents a 
      significant advance. The absolute benefit of adjuvant chemotherapy in this 
      setting is small with an overall survival improvement of 5%. In addition, there 
      are many patients who have contraindications to cisplatin-based adjuvant therapy. 
      Adjuvant chemotherapy is intended to target systemic micrometastases that remain 
      after primary resection. The observation that cancers can relapse months or years 
      after initial surgery implies that the residual micrometastases exist in a latent 
      or dormant state. The concept of tumor dormancy offers therapeutic potential 
      through induction or maintenance of the dormant state in disseminated tumor cells 
      or through eradication of these dormant cells. Cancer dormancy is a complex 
      process with multiple potential mechanisms. This review will focus on some of the 
      evidence for immune related tumor dormancy and the potential for immune therapies 
      to improve outcomes in the adjuvant setting in NSCLC.
FAU - Butts, Charles A
AU  - Butts CA
AD  - Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Transl Lung Cancer Res
JT  - Translational lung cancer research
JID - 101646875
PMC - PMC4367725
OTO - NOTNLM
OT  - Non-small cell lung cancer (NSCLC)
OT  - anti-tumor immune response
OT  - checkpoint inhibitors
OT  - gene signature (GS)
OT  - immune dormancy
OT  - immunotherapy
EDAT- 2013/10/01 00:00
MHDA- 2013/10/01 00:01
PMCR- 2013/10/01
CRDT- 2015/03/26 06:00
PHST- 2013/09/28 00:00 [received]
PHST- 2013/10/12 00:00 [accepted]
PHST- 2015/03/26 06:00 [entrez]
PHST- 2013/10/01 00:00 [pubmed]
PHST- 2013/10/01 00:01 [medline]
PHST- 2013/10/01 00:00 [pmc-release]
AID - tlcr-02-05-415 [pii]
AID - 10.3978/j.issn.2218-6751.2013.10.09 [doi]
PST - ppublish
SO  - Transl Lung Cancer Res. 2013 Oct;2(5):415-22. doi: 
      10.3978/j.issn.2218-6751.2013.10.09.